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emergency department visits in 1999–2001 by individuals aged
25–64 with primary diagnosis of pneumonia, antibiotic pre-
scription within three-days, chest x-ray on index date, continu-
ous enrollment for 12-months prior, 30-days after index visit.
Exclusion criteria: antibiotic prescription, pneumonia diagnosis,
or hospitalization in prior 30-days; initial therapy with multiple
antibiotics; in prior 12-months residence in a long-term 
care facility or diagnosis of cancer of bronchus or lung, sec-
ondary malignancy, HIV/AIDS, cystic ﬁbrosis, immunity disor-
ders. We considered the following comorbid illnesses: chronic
liver, renal or lung disease; cerebrovascular disease; cardiac
disease; diabetes mellitus; malignancy. RESULTS: A total of
5748 cases met criteria, 13.9% initially seen in the emergency
department. Of these, 16.8% had one comorbidity, 3.5% had
multiple comorbidities. Macrolides were the most common
initial therapy (66.5%), followed by quinolones (17.9%).
Quinolone use more than doubled from 1999 to 2001, from
11.8% to 24.3% in patients without comorbidity, from 12.1%
to 33.8% in patients with comorbidities. Overall, 13.1%
received a change in therapy without subsequent hospitalization,
another 3.0% were hospitalized. Females were more likely to
change therapy than males (15.9% vs. 10.5%, p < 0.0001) but
not more likely to be hospitalized (3.0% for both). Failure rates
were strongly associated with number of comorbidities (p =
0.0004), particularly in rates of subsequent hospitalization:
2.4% for no comorbidities, 4.9% for one comorbidity and 7.5%
for multiple comorbidities. Hospitalization without secondary
outpatient therapy was common: 13.5% for patients without
comorbidity, 24.9% for one comorbidity, 28.6% for multiple
comorbidities. CONCLUSION: While macrolides were the most
common therapy, quinolone usage was substantial and rising
rapidly regardless of comorbidity. Hospitalization for patients 
failing therapy was fairly common even in patients without
comorbidity.
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OBJECTIVE: Infections due to P. aeruginosa are associated with
increased likelihood of death and morbidity. Empiric therapy is
often difﬁcult due to increased resistance noted with this organ-
ism. The purpose of this study was to determine the impact of
inappropriate initial empiric therapy on health outcomes of
patients with P. aeruginosa bacteremia. METHODS: Retrospec-
tive cohort study of hospitalized patients with their ﬁrst episode
of P. aeruginosa bacteremia. Patients were stratiﬁed based on
appropriateness of antipseudomonal therapy. Inappropriate
initial empiric therapy was deﬁned as receipt of antibiotic
therapy to which the isolate displayed in vitro resistance. Data
collected included discharge mortality, new ICU admit, new
requirement for ventilator therapy or hemodialysis, and length
of hospital stay. RESULTS: A total of 87 patients (71%
males/29% females) aged 58 ± 17 years (mean ± SD) were iden-
tiﬁed between January, 2002 to April, 2004. Overall mortality
was 44%. Forty-nine percent of patients’ received inappropriate
antibiotic therapy. ApacheII score were signiﬁcantly higher in
patients that died (p = 0.003). Mortality rates were signiﬁcantly
higher in patients treated with inappropriate empiric therapy
(63%) compared to patients treated appropriately (39%, OR =
2.97, p = 0.024). New requirements for ICU admission,
hemodialysis, or ventilator did not differ between the two
groups. CONCLUSIONS: Inappropriate initial empiric therapy
in patients with P. aeruginosa bacteremia signiﬁcantly increased
mortality rates.
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OBJECTIVES: We sought to evaluate which risk factors may be
implicated in prolonged duration of antibiotic treatment in hos-
pitalized patients with complicated skin and structure infections
(cSSSI). METHODS: We pooled data from two double-blind,
randomized, multinational, clinical trials among patients with
cSSSI. Patients were randomly assigned to receive either tigecy-
cline (initial 100mg dose, followed by 50mg twice daily) or van-
comycin with aztreonam (1g vancomycin plus 2g aztreonam,
twice daily) via IV administration. Treatment termination was
based on physician assessment of resolution of signs and symp-
toms of infection, with formal test of cure (TOC) at least 12-
days later. We used a Cox proportional hazard (CPH) model 
to identify potential clinical risk factors for longer time-to-
treatment termination. RESULTS: Among 1041 patients in the
modiﬁed intent-to-treat (m-ITT) population with complete hos-
pitalization data, deep/extensive cellulitis (59%) was the most
common cSSSI diagnosis, spontaneous infection (51%) was the
typical etiology, and diabetes (22%) was the most common
comorbidity. No signiﬁcant differences were observed in baseline
characteristics. Median treatment duration was eight-days for
each treatment group. The estimated CPH model identiﬁed dia-
betes (p < 0.0001), female sex (p = 0.017), infected ulcer (p =
0.001), and use of concomitant antibiotics (p = 0.002) as inde-
pendent risk factors for signiﬁcantly longer treatment duration.
Adjusting for these risk factors, tigecycline was associated with
a trend toward shorter treatment duration overall (p = 0.072)
and within the diabetes, infected ulcer, and female strata. There
was no difference across the treatment groups in the rate of cure
at the TOC visit (p = 0.197). CONCLUSIONS: Diabetes, female
sex, infected ulcers, and use of concomitant antibiotics emerged
as signiﬁcant risk factors for prolonged treatment duration in
cSSSI. Tigecycline, the ﬁrst in a new antibiotic class, the glycyl-
cyclines, was associated with a trend toward shorter treatment
duration, once the risk factors were adjusted for.
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OBJECTIVE: The objective of this study was to determine the
impact of empiric antifungal therapy on mortality in hospital-
ized, non-neutropenic patients with bloodstream candidemia.
METHODS: Retrospective cohort study to evaluate the effect of
empiric therapy on mortality in patients with bloodstream can-
didemia. Medical and hospitalization history were collected from
the medical charts of patients hospitalized from 2002 to 2004
with their ﬁrst documented episode of candidemia. Patients were
grouped by APACHEII scores and choice of empiric antifungal
therapy (narrow spectrum: ﬂuconazole or itraconazole; broad
spectrum: amphotericin, caspofungin, or voriconazole). Impact
